Background
Researchers have indicated that they want access to novel target antibodies quickly to aid in their research. IMGENEX is pleased to be able to offer researchers access to cutting-edge products that are still in the process of characterization/validation. IMGENEX’s ‘IMX’ antibody line is shown by ELISA to bind to the peptide used as immunogen. Investigators should empirically determine the suitability of the antibody, including optimal dilutions, for other applications of interest.
 |
We cannot guarantee that the yet-to-be-fully validated antibody will work in any application other than in an ELISA against the peptide used as immunogen and therefore cannot offer a refund if the antibody does not work in your application. |
|
The antibody is offered at a lower price compared to a more highly validated antibody. |
|
We are not able to provide the immunogen for the antibodies, but do provide the amino acid sequence. |
These antibodies are not fully validated and we appreciate your feedback. Customer feedback is used to help generate testing methodologies which can lead to further product validation or withdrawal.
The caudal type homeo box transcription factors 1 (CDX1) and 2 (CDX2) are candidates for directing intestinal development, differentiation, and maintenance of the intestinal phenotype. CDX1 and CDX2 expression is widely present in the human intestinal and colonic mucosae, but not in the gastric mucosa, suggesting a possible role in the terminal differentiation of the intestine. Increased CDX2 expression is associated with chronic atrophic gastritis. Detectable expression of CDX2 precedes expression of CDX1 during the progression of intestinal metaplasia, thus expression of CDX2 may trigger the initiation and development of intestinal metaplasia. Markedly reduced or absent CDX2 expression was noted by immunohistochemistry in 13 of 15 (87%) large cell minimally differentiated carcinomas (LCMDCs), whereas only 1 of the 25 (4%) differentiated adenocarcinomas (DACs) showed reduced CDX2 expression. Thus, a significant decrease in human CDX1 and/or CDX2 expression may be associated with colorectal tumorigenesis. |
